Skip to main content
Premium Trial:

Request an Annual Quote

Artemis Pharma to Use Benitec s ddRNAi Technology for Mouse and Rat Models

NEW YORK, Oct. 28 (GenomeWeb News) - Benitec said today that it has granted a worldwide non-exclusive license to Artemis Pharmaceuticals for use of its proprietary ddRNAi technology in transgenic mouse and rat model development.


Benitec said it will receive an up-front license fee and ongoing royalties, but did not disclose additional financial details.


Artemis will use the ddRNAi technology to add in vivo gene knock-down capabilities to its ArteMice rodent model platform.


Benitec said that Artemis - a subsidiary of Exelixis based in Cologne, Germany - is the first European licensee for its ddRNAi technology.


In August, Benitec licensed the technology to GenScript and Ambion under patent infringement settlements related to its ddRNAi patent estate. A third patent infringement case, with Nucleonics, is still pending, following Nucleonics' requests to both the US and Australian patent authorities to re-examine Benitec's patents. 

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.